Cullinan Therapeutics (CGEM) Income from Non-Controlling Interests (2020 - 2026)
Cullinan Therapeutics' (CGEM) quarterly Income from Non-Controlling Interests came in at -$893000.0 in Q1 2026, down 239.97% year-on-year from $638000.0 in Q1 2025, and up 19.26% quarter-over-quarter from -$1.1 million in Q4 2025.
Cullinan Therapeutics (CGEM) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Cullinan Therapeutics' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$893000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 239.97% year-over-year to -$893000.0 in Q1 2026; TTM through Mar 2026 was -$1.9 million, a 197.83% decrease from a year earlier, with the FY2024 full-year figure at -$192000.0, up 90.1% from the prior year.
- Income from Non-Controlling Interests improved to -$893000.0 in Q1 2026 per CGEM's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.4 million in Q3 2024 and bottomed at -$2.3 million in Q1 2022.
- The 5-year median for Income from Non-Controlling Interests is -$254000.0 (2022), against an average of -$295071.4.
- Across the five-year window, Income from Non-Controlling Interests sank 475.16% in 2023 and jumped 415.84% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$306000.0 in 2022, then sank by 475.16% to -$1.8 million in 2023, then soared by 182.16% to $1.4 million in 2024, then slumped by 176.49% to -$1.1 million in 2025, then rose by 19.26% to -$893000.0 in 2026.
- Per Business Quant, the three latest CGEM Income from Non-Controlling Interests figures stand at -$893000.0 (Q1 2026), -$1.1 million (Q4 2025), and $102000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cullinan Therapeutics | 368.65 Mn | 368.65 Mn | - | -893,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -893,000.00 |
| Dec 31, 2025 | -1.11 Mn |
| Jun 30, 2025 | 102,000.00 |
| Mar 31, 2025 | 638,000.00 |
| Sep 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | -145,000.00 |
| Mar 31, 2024 | -202,000.00 |
| Dec 31, 2023 | -1.76 Mn |
| Jun 30, 2023 | -383,000.00 |
| Mar 31, 2023 | 1.36 Mn |
| Dec 31, 2022 | -306,000.00 |
| Sep 30, 2022 | -86,000.00 |
| Jun 30, 2022 | -499,000.00 |
| Mar 31, 2022 | -2.30 Mn |
| Dec 31, 2021 | -1.69 Mn |
| Sep 30, 2021 | -909,000.00 |
| Jun 30, 2021 | -803,000.00 |
| Mar 31, 2021 | 1.50 Mn |
| Dec 31, 2020 | 6.90 Mn |
| Sep 30, 2020 | -144,000.00 |